Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for GNMSF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 2003. Start Trial.
Date Value
June 30, 2026 26.23%
March 31, 2026 5.92%
December 31, 2025 2.93%
September 30, 2025 39.24%
June 30, 2025 36.32%
March 31, 2025 27.27%
December 31, 2024 59.70%
September 30, 2024 22.85%
June 30, 2024 26.06%
March 31, 2024 31.98%
December 31, 2023 13.68%
September 30, 2023 44.65%
June 30, 2023 32.02%
March 31, 2023 7.41%
December 31, 2022 11.17%
September 30, 2022 63.18%
June 30, 2022 59.80%
March 31, 2022 21.94%
December 31, 2021 27.34%
September 30, 2021 38.53%
June 30, 2021 15.52%
March 31, 2021 69.32%
December 31, 2020 28.42%
September 30, 2020 30.74%
June 30, 2020 61.97%
Date Value
March 31, 2020 30.16%
December 31, 2019 49.70%
September 30, 2019 51.65%
June 30, 2019 10.97%
March 31, 2019 12.22%
December 31, 2018 67.47%
September 30, 2018 29.93%
June 30, 2018 51.12%
March 31, 2018 29.16%
December 31, 2017 77.21%
September 30, 2017 -1.76%
June 30, 2017 39.73%
March 31, 2017 6.42%
December 31, 2016 90.72%
September 30, 2016 51.82%
June 30, 2016 47.55%
March 31, 2016 -6.77%
December 31, 2015 67.77%
September 30, 2015 50.50%
June 30, 2015 9.49%
March 31, 2015
December 31, 2014 31.98%
September 30, 2014 58.90%
June 30, 2014 -22.55%
March 31, 2014 39.87%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Ascendis Pharma A/S 61.00%
Zealand Pharma A/S 87.22%
Bavarian Nordic A/S 36.03%
Evaxion AS --
ACADIA Pharmaceuticals, Inc. 10.23%